Skip to main content

Insulet (NASDAQ: PODD) — Company Overview, News & Financial Data

Insulet logo
PODD Insulet
Insulet primary media
Company profile

Insulet

About

Explore United States companies

Insulet is a medical device manufacturer specializing in the development, production, and commercialization of tubeless insulin management systems for individuals with diabetes. Headquartered in Acton, Massachusetts, the company designs wearable, continuous subcutaneous insulin infusion pods that integrate with continuous glucose monitors and smartphone applications to automate insulin delivery. Beyond type 1 and type 2 diabetes care, the business leverages its proprietary wearable drug delivery platform for non-diabetes pharmaceutical applications through partnerships with biotechnology and pharmaceutical companies. Operating internationally across North America, Europe, the Middle East, and Asia-Pacific, the company supplies products to over 600,000 active global customers.

Snapshot

Public USOwnership
2000Year founded
5,001–10,000Employees
Acton, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
United States
Malaysia

Products and/or services of Insulet

  • Automated Insulin Delivery Systems: Wearable tubeless pods that automatically adjust insulin delivery based on real-time sensor data from integrated continuous glucose monitors, serving type 1 and type 2 diabetes patients across global markets.
  • Standalone Tubeless Insulin Management Systems: Wearable insulin delivery pods controlled by a dedicated handheld device, offering continuous subcutaneous insulin therapy with customizable basal rates and bolus dosing without requiring integrated continuous glucose monitor algorithms.
  • Type 2 Diabetes Management Products: Wearable tubeless insulin delivery systems tailored specifically for adults living with type 2 diabetes, providing simplified basal-only or basal-bolus insulin delivery options to simplify daily therapeutic administration schedules.
  • Mobile Application and Cloud Data Platforms: Digital healthcare software platforms enabling users to control wearable delivery devices via smartphones, monitor glucose levels in real time, and automatically transmit therapy data to cloud servers for clinician review.
  • Custom Drug Delivery Partner Solutions: Tailored wearable drug delivery platforms developed in collaboration with pharmaceutical and biotechnology companies for non-insulin therapeutic applications, utilizing proprietary automated pod architecture for precise subcutaneous drug administration.
  • Global Manufacturing and Supply Operations: High-volume automated manufacturing facilities located in Massachusetts and Malaysia, producing sterile wearable delivery pods and electronic controllers distributed across 26 countries to support more than 600,000 active users.

Insulet executive team

  • Ms. Flavia H. PeaseExecutive VP & CFO
  • Mr. Eric BenjaminExecutive VP & COO
  • Mr. John Wodick Kapples J.D.Senior VP & General Counsel
  • Ms. Ashley A. McEvoyCEO, President & Director
  • Mr. Amit GulianiSenior VP & CTO
  • Ms. Clare TrachtmanVice President of Investor Relations
  • Ms. Laetitia CousinSenior VP of Regulatory Affairs, Quality Assurance & Compliance
  • Ms. Angela Geryak WiczekSenior Director of Corporate Communications
  • Mr. Philip HildaleSenior Vice President of Sales & Customer Care
  • Mr. Andrew IsaacsonSenior VP of Strategy & Corporate Development